CAMBRIDGE, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicycle Therapeutics, a biotechnology company pioneering a new class of
therapeutics based on its proprietary bicyclic peptide (Bicycle®)
product platform, today announced the appointment of Lee Kalowski as
Chief Financial Officer.

“We are delighted to welcome Lee to the Bicycle team at this exciting
time for our company,” said Dr. Kevin Lee, Ph.D., Chief Executive
Officer of Bicycle Therapeutics. “He brings a wealth of experience
working with biotech companies at all stages of their evolution, both as
a Wall Street research analyst and as a public company CFO, and his
insights will prove invaluable as we continue to grow our business,
expand our pipeline and move our lead candidate, BT1718, into clinical
development.”

Prior to joining Bicycle, Mr. Kalowski served as the Chief Financial
Officer of Tokai Pharmaceuticals, Inc., where he helped lead the
company’s $105 million initial public offering in 2014. Previously, he
was vice president, global biotechnology equity research at Credit
Suisse, where he served as a senior research analyst covering the
biotechnology sector. Before that, he worked in mergers and acquisitions
in the pharmaceutical division of Johnson & Johnson and in global
pharmaceutical equity research at Sanford C. Bernstein and Prudential
Equity Group. Mr. Kalowski received a B.A. in biology and economics from
Union College and an MBA from The Wharton School of the University of
Pennsylvania.

“Bicycle has pioneered a revolutionary platform that has generated a new
class of drugs designed to target diseases more effectively,” said Mr.
Kalowski. “I am thrilled to be joining the company as the pipeline
continues to expand and as the company transitions into a clinical-stage
biotech company.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat
oncology and other important diseases based on its proprietary bicyclic
peptide (Bicycle®) product platform. Bicycles®
exhibit the affinity and exquisite target specificity usually associated
with antibodies. Their small size enables rapid and deep tissue
penetration, allowing tissues and tumors to be targeted from within.
Their peptidic nature provides a “tuneable” pharmacokinetic half-life
and a renal route of clearance, thus avoiding the liver and
gastrointestinal tract toxicity often seen with other drug modalities.
Bicycle Therapeutics is rapidly advancing towards the clinic with its
lead programs using Bicycle Drug Conjugates® to
selectively deliver toxins to tumors. Bicycle Therapeutics is
collaborating in oncology and other areas to realize the full potential
of the technology. Bicycle Therapeutics’ unique intellectual property is
based on the work initiated at the MRC Laboratory of Molecular Biology
in Cambridge, U.K., by the scientific founders of the company, Sir
Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is
headquartered in Cambridge, U.K., with a U.S. subsidiary in Cambridge,
Massachusetts. For more information, visit www.bicycletherapeutics.com.